All canine diagnoses

Your dog was diagnosed with Soft Tissue Sarcoma, Grade I–II (Wide Excision Feasible). STS represents a heterogeneous group of mesenchymal tumours with similar biological behaviour. Grade I–II tumours are locally invasive but metastatic potential is low (Grade I ~7% recurrence, Grade II ~34% recurrence after marginal excision). Compare 2 treatment options for dogs including Wide Surgical Excision, Surgical Excision + Post-Operative Radiation Therapy — with survival times, costs, and what to expect during treatment.

🐕

Soft Tissue Sarcoma, Grade I–II (Wide Excision Feasible)

BreedsLarge breed dogs generally overrepresented
canine

Mesenchymal

About This Cancer

Soft tissue sarcomas are a diverse group of cancers arising from connective tissues such as fat, muscle, fibrous tissue, nerves, and blood vessel walls. Despite their varied cell origins, these tumours share similar biological behaviour: they grow as locally invasive masses that infiltrate surrounding tissues along fascial planes, making them appear smaller on the surface than they truly are beneath the skin. Grade I–II tumours grow relatively slowly and have a low chance of spreading to distant organs, but they can recur locally if surgical margins are not wide enough. The key to successful treatment is achieving complete surgical removal with generous margins at the first operation, as recurrences tend to be more difficult to excise completely. Large breed dogs are generally overrepresented, and these tumours most commonly appear on the trunk or extremities.

STS Grading System (Kuntz)

Based on mitotic index, degree of differentiation, and percentage of necrosis.

Stage Grade IWell-differentiated, low mitotic index, minimal necrosis. 7% recurrence after marginal excision.
Stage Grade IIModerately differentiated, moderate mitotic index. 34% recurrence after marginal excision.
Stage Grade IIIPoorly differentiated, high mitotic index, significant necrosis. 75% recurrence after marginal excision. High metastatic potential.
Prognostic Factors(2)
Surgical margin statusTumour-free margins: 7% local recurrence (3-year cumulative). Close margins: 23%. Infiltrated: 42%. 11-fold higher recurrence with incomplete vs complete excision.(Milovancev et al., 2019 (PMID 30953384))
Histological gradeGrade is the strongest predictor of both local recurrence and metastatic potential.
Minimum Workup(5 steps)
1Incisional biopsy or Tru-Cut biopsy (pre-operative grading critical)
2Three-view thoracic radiographs
3Complete blood count and biochemistry
4Regional lymph node assessment
5CT or MRI of tumour site (surgical planning — assess extent of invasion)

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Wide Surgical Excision
See notes
Surgical Excision + Post-Operative Radiation Therapy
~61 mo
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.